公开(公告)号：US11592452B2

公开(公告)日：2023-02-28

申请号：US16630686

申请日：2018-07-13

申请人： MCBI INC.

发明人： Daisuke Kawakami ,  Toshiya Matsubara ,  Kazuhiko Uchida ,  Kohji Meno

IPC分类号： G01N33/68 ,  G01N30/06 ,  G01N30/72 ,  G01N30/88 ,  G01N33/60 ,  G01N27/623

摘要： The present invention is a method for detecting a specific disease based on the result of a measurement in which the amount of a peptide serving as a biomarker contained in a biological sample is determined by using an LC-MS. A pretreatment process performed before the measurement using the LC-MS includes the steps of preparing a mixed sample solution by adding a stable isotope reagent and a trifluoroacetic acid to the biological sample, where the stable isotope reagent is prepared beforehand by labeling the peptide with a stable isotope; boiling the mixed sample solution; injecting the mixed sample solution after boiled into a solid-phase extraction column to make the peptide be retained in the solid-phase extraction column; and passing a water-soluble organic solvent through the solid-phase extraction column to elute the peptide retained in the solid-phase extraction column and collect the eluate.

公开(公告)号：US10145853B2

公开(公告)日：2018-12-04

申请号：US14679332

申请日：2015-04-06

申请人： MCBI, Inc.

发明人： Kohji Meno ,  Hideaki Suzuki

IPC分类号： G01N33/68 ,  C07K14/81

摘要： The present invention aims to present methods to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis by using a protein or its partial peptide that differs in presence or absence, or in quantity between healthy human subjects and patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis or between patients with fatty liver and nonalcoholic steatohepatitis and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis. Specifically, 35 kDa protein fragment consisting of amino acid sequence expressed by Sequence No. 2 and its partial peptide consisting of amino acid sequence expressed by Sequence No. 3 (including its glycated form) of inter-alpha-trypsin inhibitor heavy chain H4 precursor consisting of amino acid sequence expressed by Sequence No. 1 could be used as biomarkers to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis.

公开(公告)号：US11543418B2

公开(公告)日：2023-01-03

申请号：US16630045

申请日：2017-07-13

申请人： MCBI INC. ,  Kazuhiko Uchida

发明人： Kazuhiko Uchida ,  Kohji Meno ,  Hideaki Suzuki

IPC分类号： G01N33/68 ,  C07K16/18

摘要： This invention provides a method for detecting cognitive disfunction diseases including mild cognitive impairment and Alzheimer's disease using a protein and a peptide of the protein different in the presence level in subjects having a normal cognitive function and patients suffering from cognitive disfunction diseases and a biomarker for detecting cognitive disfunction diseases including mild cognitive impairment and Alzheimer's disease containing the protein and the peptide. This invention is a biomarker for diagnosing cognitive disfunction diseases containing a prothrombin precursor protein of SEQ ID NO: 1 or a peptide THRB containing the amino acid sequence represented by SEQ ID NO: 2 which is a peptide of the protein, a diagnosis method for cognitive disfunction diseases using the biomarker, an antigen peptide represented by SEQ ID NO: 3 for creating a THRB peptide specific antibody to be used in the diagnosis method, and a cognitive disfunction disease diagnosis kit containing the THRB peptide specific antibody.

公开(公告)号：US11726099B2

公开(公告)日：2023-08-15

申请号：US16539829

申请日：2019-08-13

申请人： MCBI INC.

发明人： Kazuhiko Uchida ,  Takashi Ishi ,  Kohji Meno ,  Hideaki Suzuki

IPC分类号： G01N33/68 ,  C07K14/47

CPC分类号： G01N33/6896 ,  C07K14/47 ,  G01N2333/705 ,  G01N2333/974 ,  G01N2560/00 ,  G01N2800/2814 ,  G01N2800/2828

摘要： Methods are provided that detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence. Novel biomarkers are also provided for cognitive impairment and non-psychiatric disease, as well as methods for detecting cognitive impairment using such biomarkers. Specifically, a biomarker for diagnosis is provided that comprises a protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of an amino acid sequence expressed by SEQ ID NO: 1, 3, 6, 8, 10, 13, 15, 18, or 20 and selected from the group of partial peptide in these proteins consisting of an amino acid sequence expressed by SEQ ID NO: 2, 4, 5, 7, 9, 11, 12, 14, 16, 17, 19, or 21.

公开(公告)号：US11307208B2

公开(公告)日：2022-04-19

申请号：US16791984

申请日：2020-02-14

申请人： MCBI INC.

发明人： Kazuhiko Uchida ,  Kohji Meno ,  Hideaki Suzuki

IPC分类号： G01N33/48 ,  C07K14/435 ,  A61K39/00 ,  G01N33/68 ,  C07K16/40

摘要： The present invention aims to provide methods to detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence, or in quantity between non-cognitive impairment and patients with cognitive impairment and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect cognitive impairment including Alzheimer disease or mild cognitive impairment. Specifically, a biomarker for diagnosis of psychiatry disease or cognitive impairment comprising protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of amino acid sequence expressed by SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25 and selected from the group of partial peptide in these proteins consisting of amino acid sequence expressed by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 27. And further aims to provide diagnostic method using these biomarker.